Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kayed R et al. - Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the A beta peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.


Today in Neurologic/Ophthalmic...keeping you current

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
Therapeutic Advances in Neurological Disorders, 11/10/09

The management of allergic eye diseases in primary eye care
Contact Lens and Anterior Eye, 11/03/09

Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Archives of Neurology, 11/19/09

Today in Vaccine/Immunotherapy...keeping you current

Update on vaccination guidelines for allergic children
Expert Review of Vaccines, 10/29/09

Safety of vaccination of patients with systemic lupus erythematosus
Lupus, 11/04/09

Yearly influenza vaccinations: a double-edged sword
The Lancet Infectious Diseases, 11/19/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address